We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Supreme Court is seeking advice from the U.S. government on whether it should review a federal antitrust lawsuit triggered by a reverse-payment deal that delayed the launch of generic tamoxifen.
Three years after launching a combination drug, whose design could extend its patent life, Pfizer has filed a lawsuit to block a generic version of Caduet.
A five-year old patent infringement case filed by Apotex backfired when a federal court dismissed the case and ordered the company to pay $3.1 million in attorneys fees after finding its patent invalid.
A federal antitrust lawsuit filed by drug distributors against Purdue Pharma claims the drug company monopolized the oxycodone market by blocking generic versions of the drug with illegally obtained patents.
Johnson & Johnson (J&J) has disclosed that three of its subsidiaries have received three separate subpoenas from the Boston, San Francisco and Philadelphia U.S. attorneys’ offices relating to marketing practices for Risperdal, Topamax and Natrecor.
Some courts are placing drug companies in an impossible situation by failing to recognize the FDA’s preemption authority in product labeling cases, the Washington Legal Foundation (WLF) said.
Three years after launching Caduet, a combination of two blockbuster drugs some say is designed to extend patent life, Pfizer is in litigation to block a generic version of the drug.
An HIV/AIDS healthcare provider has filed a lawsuit against Pfizer, saying its marketing campaign for Viagra promoted recreational use of the drug and contributed to increased incidence of sexually transmitted diseases (STDs), including HIV.